	US 12,331,362 B2
	Methods of measuring C19MC miRNA in a post-natal tissue and uses thereof
Hana Totary-Jain, Wesley Chapel, FL (US); and Ezinne Frances Mong, Tampa, FL (US)
Assigned to UNIVERSITY OF SOUTH FLORIDA, Tampa, FL (US)
Filed by University of South Florida, Tampa, FL (US)
Filed on Oct. 25, 2021, as Appl. No. 17/509,648.
Application 17/509,648 is a division of application No. 16/594,930, filed on Oct. 7, 2019, granted, now 11,155,880.
Application 16/594,930 is a continuation of application No. 15/623,832, filed on Jun. 15, 2017, granted, now 10,435,757, issued on Oct. 8, 2019.
Claims priority of provisional application 62/350,232, filed on Jun. 15, 2016.
Prior Publication US 2022/0042113 A1, Feb. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6886 (2018.01); A61K 48/00 (2006.01); C12N 15/11 (2006.01); C12Q 1/6883 (2018.01)

CPC C12Q 1/6886 (2013.01) [A61K 48/005 (2013.01); C12N 15/11 (2013.01); C12Q 1/6883 (2013.01); C12N 2310/20 (2017.05); C12Q 2600/154 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/178 (2013.01)]

10 Claims

1. A method of detecting a C19MC miRNA in a post-natal tissue or bodily fluid comprising:

(a) obtaining a sample of post-natal tissue or post-natal bodily fluid from a subject; and

(b) measuring the amount or expression of a C19MC miRNA in the sample, and

(c) detecting an increase in the expression of the C19MC miRNA in the sample as compared to a wild-type, normal, or un-diseased control,

wherein the C19MC miRNA has a polynucleotide sequence that is 90% to 100% identical to any one of SEQ ID NOs: 1-94,

wherein infantile hemangioma (IH), infantile hepatic hemangioma, infantile brain tumor, or other infantile tumor that expresses C19MC is diagnosed when the C19MC miRNA measured has an increased amount or expression as compared to a wild-type, normal, or un-diseased control,

and wherein the infantile brain tumor is embryonal tumor with multilayer rosettes (ETMR), medulloblastoma, or other embryonal tumors.